Clinical Trial Update: Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TKI258 in relapsed or refractory multiple myeloma, with or without t(4;14) translocation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TKI258

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED